1. Home
  2. VINP vs NTLA Comparison

VINP vs NTLA Comparison

Compare VINP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VINP
  • NTLA
  • Stock Information
  • Founded
  • VINP 2009
  • NTLA 2014
  • Country
  • VINP Brazil
  • NTLA United States
  • Employees
  • VINP N/A
  • NTLA N/A
  • Industry
  • VINP Investment Managers
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • VINP Finance
  • NTLA Health Care
  • Exchange
  • VINP Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • VINP 634.1M
  • NTLA 710.1M
  • IPO Year
  • VINP 2021
  • NTLA 2016
  • Fundamental
  • Price
  • VINP $9.52
  • NTLA $8.09
  • Analyst Decision
  • VINP Strong Buy
  • NTLA Buy
  • Analyst Count
  • VINP 2
  • NTLA 20
  • Target Price
  • VINP $13.25
  • NTLA $36.60
  • AVG Volume (30 Days)
  • VINP 51.7K
  • NTLA 5.4M
  • Earning Date
  • VINP 05-12-2025
  • NTLA 05-08-2025
  • Dividend Yield
  • VINP 6.67%
  • NTLA N/A
  • EPS Growth
  • VINP N/A
  • NTLA N/A
  • EPS
  • VINP 0.38
  • NTLA N/A
  • Revenue
  • VINP $126,696,258.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • VINP $70.28
  • NTLA N/A
  • Revenue Next Year
  • VINP $14.37
  • NTLA N/A
  • P/E Ratio
  • VINP $24.80
  • NTLA N/A
  • Revenue Growth
  • VINP 57.51
  • NTLA N/A
  • 52 Week Low
  • VINP $8.66
  • NTLA $5.90
  • 52 Week High
  • VINP $11.62
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • VINP 41.29
  • NTLA 49.10
  • Support Level
  • VINP $9.43
  • NTLA $7.31
  • Resistance Level
  • VINP $9.85
  • NTLA $9.79
  • Average True Range (ATR)
  • VINP 0.23
  • NTLA 0.58
  • MACD
  • VINP -0.05
  • NTLA -0.12
  • Stochastic Oscillator
  • VINP 20.37
  • NTLA 42.64

About VINP Vinci Partners Investments Ltd.

Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: